| Literature DB >> 33319786 |
A Castrioto1,2, S Thobois3,4, M Anheim5,6,7, J L Quesada8, E Lhommée9,10, H Klinger4, A Bichon9,10, E Schmitt9,10, F Durif11, J P Azulay12, J L Houeto13, N Longato5, C Philipps6, P Pelissier9, E Broussolle3,4, E Moro9,10, C Tranchant5,6,7, V Fraix9,10, P Krack14.
Abstract
Management of apathy, depression and anxiety in Parkinson's disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and anxiety in de novo PD. The primary outcome was the change of apathy, measured with the LARS. The secondary outcomes were the change in depression and anxiety, measured with BDI-2 and STAI-trait and state. Forty-eight drug-naive PD patients were included. The primary outcome was not reached, with a surprisingly high placebo effect on apathy (60%). There was no significant difference in the change of depression at 6 months between rotigotine and placebo. Trait-anxiety was significantly improved by rotigotine compared to placebo (p = 0.04). Compared to placebo, low dose rotigotine significantly improved trait anxiety, but not apathy and depression. The major placebo effect on apathy points towards the importance of a multidisciplinary and tight follow-up in the management of neuropsychiatric symptoms.Entities:
Year: 2020 PMID： 33319786 DOI： 10.1038/s41531-020-00142-x
Source DB: PubMed Journal: NPJ Parkinsons Dis ISSN： 2373-8057